Real-World Treatment Patterns, Outcomes, and Healthcare Resource Utilization in Relapsed or Refractory Multiple Myeloma: Evidence from a Medical Record Review in France
Table 3
Health care utilization from first relapse to last available follow-up.
All Patients
Risk Category at Initial MM Diagnosis
High Risk
Standard Risk
n
n
n
All patients, n ()
200
100.0
55
100.0
113
100.0
Inpatient hospitalizations
Had ≥ 1 hospitalization, n (%)
70
35.0
23
41.8
32
28.3
No. hospitalizations per person-year
0.24
0.34
0.15
Emergency department visits
Had ≥ 1 visit, n (%)
54
27.0
16
29.1
28
24.8
No. visits per person-year
0.23
0.25
0.15
Office visits
Had ≥ 1 visit, n (%)
62
31.0
16
29.1
33
29.2
No. visits per person-year
1.20
1.07
0.97
Hospital outpatient/day visits
Had ≥ 1 visit, n (%)
136
68.0
38
69.1
77
68.1
No. visits per person-year
4.65
4.68
4.60
High risk: gene rearrangements del(17p), t(4;14), or t(14;16). Standard risk: all patients with known cytogenetics not classified as high risk.
